UP!

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-08 Future report Set alerts
Q3 2020 2020-11-10 Future report Set alerts
Q2 2020 2020-08-10 -1.28 -1.28
Q1 2020 2020-05-05 -0.47 -0.47
Q4 2019 2020-03-10 -0.79 -0.79
Q3 2019 2019-11-12 -0.46 -0.46
Q2 2019 2019-08-08 -0.49 -0.49
Q1 2019 2019-05-09 -0.62 -0.62
Q4 2018 2019-03-18 -0.23 -0.87
Q3 2018 2018-11-08 -0.46 -0.46

Ratings

2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-05-16 Reiterated Rating HC Wainwright Buy
2016-05-08 Reiterated Rating Brean Capital Buy
2016-05-08 Reiterated Rating Morgan Stanley Buy
2016-03-16 Initiated Coverage Brean Capital Buy
2016-03-16 Lower Price Target Needham & Company LLC Buy $18.00 to $14.00
2016-03-16 Lower Price Target HC Wainwright Buy $25.00 to $18.00
2016-03-10 Lower Price Target HC Wainwright Buy $25.00 to $18.00
2016-03-10 Initiated Coverage Brean Capital Buy $26.00
2016-03-09 Lower Price Target JMP Securities Market Outperform $24.00 to $16.00
2016-03-09 Lower Price Target JPMorgan Chase & Co. Market Outperform $24.00 to $16.00
2016-01-20 Initiated Coverage Credit Suisse Neutral $10.00
2016-01-20 Initiated Coverage Credit Suisse Group AG Neutral $10.00
2015-12-15 Reiterated Rating Brean Capital Buy
2015-12-15 Boost Price Target HC Wainwright Buy $24.00 to $25.00
2015-12-14 Boost Price Target Needham & Company LLC Buy $14.00 to $18.00
2015-12-07 Initiated Coverage HC Wainwright Buy $24.00
2015-11-10 Reiterated Rating Brean Capital Buy $26.00
2015-10-06 Initiated Coverage Brean Capital Buy
2015-10-06 Reiterated Rating Needham & Company LLC Buy $14.00
2015-09-29 Reiterated Rating Brean Capital Buy $26.00
2015-09-09 Upgrade Morgan Stanley Equal Weight to Overweight $10.00 to $17.00
2015-09-09 Boost Price Target Brean Capital Buy $18.00 to $26.00
2015-08-13 Initiated Coverage Morgan Stanley Equal to Equal Weight $10.00
2015-08-12 Reiterated Rating Brean Capital Buy $18.00
2015-06-22 Initiated Coverage JMP Securities Outperform $24.00
2015-06-04 Set Price Target Brean Capital Buy $18.00
2015-05-14 Initiated Coverage Brean Capital Buy $18.00
2015-05-12 Reiterated Rating Nomura Buy $37.00 to $27.00
2015-05-12 Reiterated Rating Nomura Holdings Inc. Buy $37.00 to $27.00
2015-05-11 Initiated Coverage Needham & Company LLC Buy $14.00
2014-11-07 Reiterated Rating Nomura Buy $39.00
2014-04-14 Initiated
2014-04-14 Initiated Coverage Nomura Buy $39.00 to $16.86
2014-04-14 Initiated Coverage Credit Suisse Outperform $25.00
2014-04-14 Initiated Coverage Morgan Stanley Overweight $90.00
2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-05-16 Reiterated Rating HC Wainwright Buy
2016-05-08 Reiterated Rating Brean Capital Buy
2016-05-08 Reiterated Rating Morgan Stanley Buy
2016-03-16 Initiated Coverage Brean Capital Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Novartis Bioventures Ltd 16.81%  (3405764) AKBA / CLDN / MRNA / PIP / TKAI /
Satter Muneer A 14.99%  (3037042) AKBA / TKAI / VTL /
Novo A/S SEE REMARKS 7.48%  (1516387) AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH /
Butler John P. President and CEO 2.02%  (408814) AKBA / KERX / RLYP /
Shalwitz Robert Chief Medical Officer 1.31%  (264556) AKBA /
Hadas Nicole R. See Remarks 0.59%  (120078) AKBA /
Dahan Michel SVP, Chief Business Officer 0.57%  (115226) AKBA /
Amello Jason SVP, CFO & Treasurer 0.43%  (87236) AKBA / OPXA / ZIOP /
Maroni Bradley SVP & Chief Medical Officer 0.32%  (64585) AKBA /
Tubridy Karen L SVP, Chief Development Officer 0.20%  (41518) AKBA / EBIO /
Jain Rita SVP, Chief Medical Officer 0.15%  (29400) AKBA /
Nash Duane 0.11%  (21499) AKBA / VTL /
Renaud Ronald C JR 0.02%  (5000) AKBA / CMRX / IDIX / PTCT /
WYZGA MICHAEL S 0.01%  (1500) AKBA / EXAS / IDIX / OMED / RDUS /
GOWEN MAXINE 0.01%  (1300) AKBA / IDRA / TRVN /

Comments